BMY Q4 2025 earnings call recap: growth portfolio momentum, pipeline catalysts, 2026 guidance, and Eliquis LOE risks.

Bristol-Myers Squibb Co (BMY) reports robust growth in its new product portfolio while navigating revenue declines in its legacy offerings.

Bristol Myers Squibb is leaning heavily on its key newer products, grouped into its growth portfolio category, to weather the ...

The researchers note that circadian rhythms - the 24-hour cycles governing biological processes - are known to influence ...

Some cancer therapies may be more effective when given earlier in the day, aligning treatment with the body's natural rhythms ...

A new study highlights the critical role of advanced AI-integrated battery management system technologies in monitoring, optimizing, and predicting battery performance for reliable and sustainable ...

Brain microphysiological systems are reshaping in vitro neurotoxicity testing through functional validation and advanced ...

Artemis II echoes the Apollo-era missions that paved the way for the first moon landing — and sets the stage for what comes ...

Explore how project management information systems guide each project phase, the tools that support them, and real-world use across industries.

Experts explore 3-year clinical data on bimekizumab presented at the 2025 EADV and SHSA congresses, highlighting its durable and ...

While many people are growing deeply concerned about the negative impact artificial intelligence might have on our fragile ...